Karapetis et al. [13] (2008) analysed tumor samples, obtained from 394 out of 572 patients with CRC who were randomly allocated to receive cetuximab and it was identified that MT KRAS did not benefit from cetuximab, whereas WT KRAS got benefit from cetuximab. The gene discussed is KRAS; the disease is neoplasm.